Sinalização PI3K/Akt/mTOR
Os inibidores da sinalização PI3K/Akt/mTOR são compostos que têm como alvo as vias da fosfoinositídeo 3-quinase (PI3K), da quinase Akt e do alvo da rapamicina em mamíferos (mTOR). Essas vias são reguladores críticos do crescimento celular, sobrevivência, metabolismo e autofagia, tornando-os alvos-chave na pesquisa de câncer e distúrbios metabólicos. A inibição dessas vias pode ajudar a controlar o crescimento e a proliferação tumoral, oferecendo estratégias terapêuticas potenciais para vários tipos de câncer e outras doenças caracterizadas por sinalização celular desregulada. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de alta qualidade de PI3K/Akt/mTOR para apoiar sua pesquisa em oncologia, sinalização celular e doenças metabólicas.
Subcategorias de "Sinalização PI3K/Akt/mTOR"
- AMPK(159 produtos)
- ATM/ATR(71 produtos)
- DNA-PK(50 produtos)
- EGFR(572 produtos)
- MELK(7 produtos)
- PDK(9 produtos)
- PI3K(241 produtos)
- S6 Quinase(9 produtos)
- gsk-3(111 produtos)
- mTOR(145 produtos)
Exibir 2 mais subcategorias
Foram encontrados 1025 produtos de "Sinalização PI3K/Akt/mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
NSC381467
CAS:<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C20H16O7Cor e Forma:SolidPeso molecular:368.34NU5455
CAS:<p>NU5455 is a potent DNA-PKcs inhibitor, oral, boosts doxorubicin in liver tumors, amplifies topoisomerase inhibitors, no adverse effects.</p>Fórmula:C34H33N3O5SCor e Forma:SolidPeso molecular:595.71EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Fórmula:C21H23N3O5Cor e Forma:SolidPeso molecular:397.424EGFR-IN-23
CAS:<p>EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.</p>Fórmula:C36H44BrN10O3PCor e Forma:SolidPeso molecular:775.68LAS195319
CAS:<p>LAS195319 is a potent and selective inhaled PI3Kδ Inhibitor (IC50 = 0.5 nM) for the Treatment of Respiratory Diseases.</p>Fórmula:C29H26N10O3SCor e Forma:SolidPeso molecular:594.65AZD 3147
CAS:<p>AZD 3147 inhibits mTORC1 (40.7 nM), mTORC2 (5.75 nM), and PI3Kα/β/δ/γ (912/5495/9333/6310 nM IC50s).</p>Fórmula:C24H31N5O4S2Pureza:99.99%Cor e Forma:SolidPeso molecular:517.66Aldometanib
CAS:<p>Aldometanib (LXY-05-029) is an oral aldolase inhibitor that maintains metabolic balance by blocking FBP and activating lysosomal AMPK.</p>Fórmula:C27H43Cl2IN2Pureza:99.32% - 99.55%Cor e Forma:SolidPeso molecular:593.46BAY-8400
<p>BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase ( DNA-PK ) inhibitor ( IC 50 =81 nM) which shows synergistic efficacy in</p>Fórmula:C21H17F2N5OPureza:99.53%Cor e Forma:SolidPeso molecular:393.39EGFR-IN-7
CAS:<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Fórmula:C32H41BrN9O2PPureza:95.32% - 99.64%Cor e Forma:SolidPeso molecular:694.6TLC9995-0188
CAS:<p>Tyrosine-protein kinase ABL, IC50: 1500 nM</p>Fórmula:C16H15N5Cor e Forma:Yellow SolidPeso molecular:277.331HMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Cor e Forma:Odour LiquidAS-604850
<p>AS-604850: PI3Kγ inhibitor, ATP-competitive, IC50=2.5μM, 30x> PI3Kδ/β, 18x> PI3Kα.</p>Fórmula:C11H5F2NO4SPureza:98%Cor e Forma:SolidPeso molecular:285.22Nimotuzumab (powder)
CAS:<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Cor e Forma:LiquidmTORC1-IN-1
<p>mTORC1-IN-1 (T1), a rapamycin homologue (rapalog) and selective inhibitor of mTORC1, controls cell growth and metabolism, with implications in various diseases</p>Pureza:98%Cor e Forma:Odour SolidAZD8154
CAS:<p>AZD8154 is a newly developed inhaled compound that selectively inhibits dual PI3Kγδ, aimed at treating airway inflammatory diseases.</p>Fórmula:C27H29N5O4S2Cor e Forma:SolidPeso molecular:551.68Sonolisib
CAS:<p>Sonolisib is an irreversible and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)).</p>Fórmula:C29H35NO8Pureza:98%Cor e Forma:SolidPeso molecular:525.59Duligotuzumab
CAS:<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Pureza:95%Cor e Forma:LiquidRef: TM-T80604
Produto descontinuadoEGFR-IN-82
CAS:<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Fórmula:C32H41BrN9O2PPureza:98%Cor e Forma:SolidPeso molecular:694.6Ref: TM-T78788
Produto descontinuadoBisindolylmaleimide I HCl
CAS:<p>Bisindolylmaleimide I HCl is a specific ATP-competitive PKC inhibitor.</p>Fórmula:C25H25ClN4O2Pureza:98%Cor e Forma:SolidPeso molecular:448.95YK-029A
CAS:<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Fórmula:C27H32N8O2Pureza:98%Cor e Forma:SolidPeso molecular:500.6Ref: TM-T79461
Produto descontinuadoMDVN1003
CAS:<p>MDVN1003 inhibits BTK & PI3Kδ in B cells, blocking NHL growth; it kills lymphoma cells, not erythroblasts.</p>Fórmula:C22H20FN7OPureza:98%Cor e Forma:SolidPeso molecular:417.44Duvelisib (R enantiomer)
CAS:Duvelisib R enantiomer (IPI-145 R enantiomer) is an enantiomer of Duvelisib with lower activity. Duvelisib is a PI3K inhibitor.Fórmula:C22H17ClN6OPureza:98%Cor e Forma:SolidPeso molecular:416.86PI3Kδ-IN-13
CAS:<p>PI3Kδ-IN-13 (compound 89), with an IC50 value of 2.6 nM, is an inhibitor of PI3Kδ, applicable for researching diseases involving cell proliferation, including</p>Fórmula:C27H39N7O4S2Cor e Forma:SolidPeso molecular:589.77EGFR-IN-122
CAS:<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Fórmula:C19H20N4O3Cor e Forma:SolidPeso molecular:352.39Ref: TM-T200157
Produto descontinuadoEGFR-IN-123
CAS:<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Fórmula:C24H27F3N6OCor e Forma:SolidPeso molecular:472.51Ref: TM-T200485
Produto descontinuado
